Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer

Published:2022-12 Issue:8 Volume:22 Page:792-800
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Wong Vanessa^ORCID,de Boer Richard,Baron-Hay Sally,Blum Robert,Boyle Frances,Chua Susan,Clarke Kerrie,Cuff Katharine,Green Michael,Lim Elgene,Mok Kelly,Nott Louise,Nottage Michelle,Tafreshi Ali,Tsoi Daphne,Uccellini Anthony,Hong Wei,Gibbs Peter,Lok Sheau Wen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

2. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [published correction appears in N Engl J Med. 2018 Dec 27;379:2582];Hortobagyi;N Engl J Med,2016

3. Overall survival with ribociclib plus letrozole in advanced breast cancer;Hortobagyi;N Engl J Med,2022

4. Demonstrating the feasibility of collecting secondary, de-identified data on Australian patients receiving treatment as part of a Medicine Access Programme;Lok;Intern Med J,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand;BMC Cancer;2024-08-16

2. Cardiovascular complications of ribociclib in breast cancer patients;Critical Reviews in Oncology/Hematology;2024-04

3. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study;JCO Global Oncology;2024-04

4. Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors;Acta Pharmaceutica;2023-12-01

5. Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision;Meditsinskiy sovet = Medical Council;2023-07-29